Key Clinical Trials
A randomized, double blind, placebo controlled study of SD-809 extended release for the treatment of chorea associated with Huntington’s disease.
FDA Approval April 2017
A randomized, double-blind, placebo-controlled, study of tetrabenazine for the treatment of Huntington’s chorea.
FDA Approval August 2008
A study in individuals with late prodromal and early manifest Huntington’s disease to access the safety, tolerability, pharmacokinetics, and efficacy of pepinemab. (VX15/2503)
A 2 x 2 factorial, double-blind, placebo-controlled, phase III multi-center clinical trial in participants with early Parkinson’s disease to assess the efficacy of tocopherol and deprenyl.
A randomized, double-blind, placebo-controlled, phase III, study to define the safety, tolerability, clinical and exploratory biological activity of the chronic administration of Nilotinib in participants with Parkinson's disease.
A Phase III double-blind placebo-controlled parallel group study of isradipine as a disease modifying agent in participants with early Parkinson’s disease.
The Parkinson’s Progression Markers Initiative is a global, longitudinal observational study seeking markers of progression in Parkinson’s disease.
Other Rare Neurological Disorders
A randomized, controlled study of acetazolamide vs. dichlorphenamide vs. placebo in individuals with hyperkalemic and hypokalemic periodic paralysis.
FDA Approval August 2015
Friedreich’s Ataxia Clinical Outcome Measure Study.
Randomized, placebo-controlled clinical trial evaluating the safety, pharmacokinetics, and efficacy of Actimmune in children and young adults with Friedreich's ataxia.
We have conducted additional clinical trials for other conditions, including dental caries, epilepsy, HIV, influenza, intracranial hypertension, stroke, and testicular cancer.